Infant Bacterial Therapeutics (IBT) Chief Scientific Officer, Eamonn Connolly, PhD has been invited to speak and be a facilitator at the 2019 NEC Symposium in the session “Promising Novel Therapies for NEC in Preclinical and Clinical Trials”. Dr. Connolly will speak about IBT´s pharmaceutical development program for the prevention of necrotizing enterocolitis in preterm infants, under the title “Drug development for the prevention of NEC”.
As the only company presenting at the symposium, IBT has a unique opportunity to share its experience with the development of IBP-9414 and maintain the continuing dialogue with key stakeholders.
The NEC Symposium takes place during June 2019. The event is organised by the NEC Society, and serves as a forum to establish a collaboration of stakeholders in NEC to accelerate the implementation and standardization of established evidence based practices that can help to reduce the incidence and morbidity of NEC. The NEC Symposium audience ranges from family members of infants who died from or survived NEC, to expert neonatologists, key opinion leaders, neonatal care practitioners and the US Food and Drug Administration.
The NEC Society, a non-profit organization, was launched in 2014 and is spearheaded by two mothers who lost their own babies to NEC. The NEC Society is a clinician-family collaborative organization in the United States who seek to improve outcomes for infants at risk of necrotizing enterocolitis. If you would like to find out more about the NEC Society, or the symposium, please see the website NEC Society.